Evidence map›Paper›PMID 41327488›Full record

ArticleBiomarker research2025

Mega-scale single-cell profiling reveals novel biomarkers associated with acute GvHD after allogeneic hematopoietic stem cell transplantation.

Zheng Song, Evgeny Klyuchnikov, Anita Badbaran, Likai Tan, Regine J Dress, Emilia Czajkowski, Simeon Weßler, Radwan Massoud, Christine Wolschke, Anja Schimrock and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomarker research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Zheng Song *Institute of Systems Immunology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20251, Hamburg, Germany.
Evgeny Klyuchnikov *Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20251, Hamburg, Germany.
Anita BadbaranDepartment of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20251, Hamburg, Germany.
Likai TanDepartment of Anaesthesia and Intensive Care and Peter Hung Pain Research Institute, The Chinese University of Hong Kong, 4/F Main Clinical Block and Trauma Centre, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China.
Regine J DressInstitute of Systems Immunology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20251, Hamburg, Germany.
Emilia CzajkowskiInstitute of Systems Immunology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20251, Hamburg, Germany.
Simeon WeßlerInstitute of Systems Immunology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20251, Hamburg, Germany.
Radwan MassoudDepartment of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20251, Hamburg, Germany.
Christine WolschkeDepartment of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20251, Hamburg, Germany.
Anja SchimrockInstitute of Immunology, Hannover Medical School; Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
Yu ZhangInstitute of Systems Immunology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20251, Hamburg, Germany.
Cedric LyHamburg Center for Translational Immunology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20251, Hamburg, Germany.
Nico GagelmannDepartment of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20251, Hamburg, Germany.
Kristin RathjeDepartment of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20251, Hamburg, Germany.
Boris FehseDepartment of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20251, Hamburg, Germany.
Stefan BonnHamburg Center for Translational Immunology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20251, Hamburg, Germany.
Sarina RavensInstitute of Immunology, Hannover Medical School; Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
Nicola GaglianiHamburg Center for Translational Immunology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20251, Hamburg, Germany.
Christian F KrebsHamburg Center for Translational Immunology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20251, Hamburg, Germany.
Ulf PanzerHamburg Center for Translational Immunology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20251, Hamburg, Germany.
Francis AyukDepartment of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20251, Hamburg, Germany.
Nicolaus Kröger *Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20251, Hamburg, Germany.
Immo Prinz *Institute of Systems Immunology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20251, Hamburg, Germany. i.prinz@uke.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlloreactive T cells mediate graft-versus-leukemia (GvL) reactions and acute graft-versus-host disease (aGvHD) in AML patients following allogeneic hematopoietic stem cell transplantation.

methodsTo investigate biomarkers that identify alloreactive T cells associated with either beneficial GvL or detrimental aGvHD, we collected graft samples and two post-transplant follow-up blood samples (day 30 and day 100) of ten AML patients undergoing hematopoietic stem cell transplantation and profiled over 777,000 CD45

resultsUsing immune receptor sequences as intrinsic clonal barcodes, we observed that especially CD8

conclusionsIn conclusion, mega-scale single-cell monitoring of graft and hematopoietic immune cell reconstitution allowed us to demonstrate that MDGA1 and ADGRG1 may function as complementary biomarkers expressed by distinct circulating T cells that are associated with divergent outcomes in AML patients, enabling precise risk stratification of alloHSCT outcomes and presenting potential therapeutic targets.

Indexed as

aGvHDalloHSCTAMLGvLMega-scale scRnAseqαβ and γδ T cell persistence

Identifiers

PMID41327488
PMCPMC12670839

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.